rethinkTHC Search
Menu
Study breakdown

Using Sativex as a Replacement Therapy for Cannabis Dependence

ReviewModerate evidence
The takeaway

Nabiximols (Sativex), containing both THC and CBD, is being investigated as a cannabinoid replacement therapy for cannabis dependence, similar to how methadone is used for opioid dependence.

Read this if you are struggling to quit cannabis and want to know about emerging pharmacological treatments.

Cannabinoid replacement therapy: controlled THC/CBD to manage cannabis withdrawal and craving

What the researchers found

The review outlines a novel approach to treating cannabis dependence using nabiximols (Sativex), a buccal spray containing THC and CBD. The rationale is analogous to opioid substitution therapy: providing a controlled, pharmaceutical-grade cannabinoid formulation to manage withdrawal and craving while patients engage in behavioral treatment.

The advantages of nabiximols over smoked cannabis include: controlled dosing, pharmaceutical-grade standardization, slower onset (reducing abuse potential), inclusion of CBD (which may modulate THC effects and has anxiolytic properties), and a delivery method that avoids the harms of smoking.

Recent research findings relevant to clinical practice are reviewed, though the approach remains investigational.

Why it matters

Cannabis dependence treatment currently has no FDA-approved medications. Cannabinoid replacement therapy represents a paradigm shift that applies lessons learned from opioid substitution therapy to cannabis treatment, potentially offering a new evidence-based approach.

The numbers in context

Nabiximols contains THC and CBD in approximately 1:1 ratio. Delivered as buccal spray. Approach modeled on opioid substitution therapy (methadone, buprenorphine).

How the study worked

This is a narrative review outlining the rationale and evidence for using nabiximols as a cannabinoid replacement therapy. It reviews the pharmacological basis for the approach and recent relevant research.

What this study cannot tell us

Clinical trial evidence for this approach was limited at the time of publication. The regulatory pathway for using a cannabinoid to treat cannabinoid dependence is complex. Long-term outcomes, optimal treatment duration, and appropriate patient selection criteria are unknown.

How to read the evidence

This is a narrative review proposing a novel treatment approach with limited but promising clinical evidence.

When this study was published

Published in 2015. Clinical trials of nabiximols for cannabis dependence have continued, with some positive results.

The bigger picture

The concept of using a controlled cannabinoid to treat cannabis dependence has historical parallels in the successful use of methadone and buprenorphine for opioid dependence. If effective, cannabinoid replacement therapy could fill a significant treatment gap.

Questions still open

  • Would cannabinoid replacement therapy improve treatment retention? Is the CBD component essential or would THC alone suffice? What is the optimal treatment duration before tapering?

Common questions

How is this different from just using cannabis?
Nabiximols provides a controlled dose of THC and CBD through a slow-onset buccal spray, reducing the reinforcing "high" associated with smoked cannabis. The pharmaceutical standardization ensures consistent dosing, and the delivery method eliminates smoking-related harms.
Is this available as a treatment?
Nabiximols for cannabis dependence remains investigational. While Sativex is approved for MS spasticity in some countries, its use for cannabis dependence has not received regulatory approval. Clinical trials are ongoing.

Read the original research

Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.

Clinical pharmacology and therapeutics, 97(6), 571-4

Citation

Allsop, D J; Lintzeris, N; Copeland, J; Dunlop, A; McGregor, I S. (2015). Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.. Clinical pharmacology and therapeutics, 97(6), 571-4. https://doi.org/10.1002/cpt.109

Explore the wider topic